

NGFRAP1 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a partial recombinant NGFRAP1. Catalog # AT3046a

Product Information

Application WB, E
Primary Accession Q00994
Other Accession BC003190
Reactivity Human
Host mouse
Clonality monoclonal
Isotype IgG2b Kappa

Clone Names 4E6 Calculated MW 12959

Additional Information

Gene ID 27018

Other Names Protein BEX3, Brain-expressed X-linked protein 3, Nerve growth factor

receptor-associated protein 1, Ovarian granulosa cell 130 kDa protein HGR74, p75NTR-associated cell death executor, NGFRAP1, BEX3, DXS6984E, NADE

Target/Specificity NGFRAP1 (AAH03190, 1 a.a. ~ 110 a.a) partial recombinant protein with GST

tag. MW of the GST tag alone is 26 KDa.

Dilution WB~~1:500~1000 E~~N/A

Format Clear, colorless solution in phosphate buffered saline, pH 7.2.

Storage Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.


Precautions NGFRAP1 Antibody (monoclonal) (M01) is for research use only and not for

use in diagnostic or therapeutic procedures.


References

Toward a confocal subcellular atlas of the human proteome. Barbe L, et al. Mol Cell Proteomics, 2008 Mar. PMID 18029348. The TSC1 gene product hamartin interacts with NADE. Yasui S, et al. Mol Cell Neurosci, 2007 May. PMID 17355907. Characterization of human dopamine responsive protein DRG-1 that binds to p75NTR-associated cell death executor NADE. Yu Y, et al. Brain Res, 2006 Jul 19. PMID 16777077. Towards a proteome-scale map of the human protein-protein interaction network. Rual JF, et al. Nature, 2005 Oct 20. PMID 16189514. Characterization of the Bex gene family in humans, mice, and rats. Alvarez E, et al. Gene, 2005 Aug 29. PMID 15958283.

Images



Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (37.73 KDa) .



Detection limit for recombinant GST tagged NGFRAP1 is approximately 0.3ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.